Idiopathic Pulmonary Fibrosis market seen doubling by 2030

Allied Market Research projects the global idiopathic pulmonary fibrosis market will grow from $3.12 billion in 2020 to $6.16 billion by 2030, driven by rising cancer cases, smoking and reimbursement support. Pirfenidone, retail pharmacies and North America led the market in 2020, while Asia-Pacific is forecast to grow fastest.

Why it matters: - The idiopathic pulmonary fibrosis market is expected to nearly double by 2030, signaling sustained demand for treatment options in a disease area with limited therapies. - Growth in reimbursement support and pipeline drug development could shape access and competition across major regions and channels. - The report is aimed at manufacturers, investors, shareholders and new entrants weighing where future revenue may concentrate.

What happened: - Allied Market Research released a report on the global idiopathic pulmonary fibrosis market covering drug type and distribution channel trends through 2030. - The market was valued at $3.12 billion in 2020 and is projected to reach $6.16 billion by 2030. - The forecast implies a 7.0% compound annual growth rate from 2021 to 2030. - The report covers Nintedanib and Pirfenidone, plus hospital pharmacies, retail pharmacies and online providers.

The details: - Rising cancer incidence worldwide, favorable reimbursement policies from manufacturers and insurance providers, and higher cigarette smoking rates are key growth drivers. - The lack of proper treatment options is restraining market expansion. - More pipeline drugs and untapped demand in developing countries create additional opportunities. - Pirfenidone held about three-fourths of the market in 2020 and is expected to keep the lead through 2030. - Pirfenidone is also projected to post the fastest drug-type CAGR at 7.2% through 2030, helped by adoption of brands such as Esbriet and Pirespa. - Retail pharmacies accounted for nearly half of market revenue in 2020 and are expected to remain the leading distribution channel. - Online providers are forecast to grow the fastest among channels at a 8.5% CAGR, supported by discounts and broader drug selection. - North America held more than two-fifths of global revenue in 2020 and is projected to remain the top regional market by 2030. - Asia-Pacific is expected to post the fastest regional CAGR at 8.9% during the forecast period. - The report names AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, GNI Group, F. Hoffmann-La Roche, Shionogi, Mission Therapeutics, Biogen, Galapagos and FibroGen among the market's companies. - Get the sample report. - Purchase the report.

Between the lines: - The market's growth profile suggests a mix of established therapies and room for newer entrants, especially in regions with weaker treatment access. - Fast growth in online distribution points to a broader shift in how specialty drugs may reach patients. - North America's lead reflects higher R&D spending and stronger healthcare infrastructure, while Asia-Pacific's acceleration reflects improving research capacity and economic development.

What's next: - Competitive positioning is likely to center on drug adoption, reimbursement access and regional expansion. - Asia-Pacific and online distribution channels may draw more attention from companies seeking faster growth. - Pipeline progress will matter because the report identifies treatment gaps as a key constraint today.